Covid-19: Oxford University Vaccine is Highly Effective

Covid-19: Oxford University Vaccine is Highly Effective
Photo Credit: Oxford University/John Cairns

The coronavirus vaccine developed by the University of Oxford is highly effective at stopping people from developing Covid-19 symptoms, a large trial, shows.

Interim data suggests 70% protection, but the researchers say the figure may be as high as 90% by tweaking the dose.

The results will be seen as a triumph, but come after Pfizer and Moderna vaccines showed 95% protection.

However, the Oxford jab is far cheaper and is easier to store and get to every corner of the world than the other two.

So, the vaccine will play a significant role in tackling the pandemic, if it is approved for use by regulators.

"The announcement today takes us another step closer to the time when we can use vaccines to bring an end to the devastation caused by [the virus]," said the vaccine's architect, Prof Sarah Gilbert.

The UK government has pre-ordered 100 million doses of the Oxford vaccine, and AstraZeneca says it will make three billion doses for the world next year.

Prime Minister Boris Johnson said it was "incredibly exciting news" and that while there were still safety checks to come, "these are fantastic results".

The vaccine has been developed in around 10 months, a process that normally takes a decade.

There are two results from the trial of more than 20,000 volunteers in the UK and Brazil.

Overall, there were 30 cases of Covid in people who had two doses of the vaccine and 101 cases in people who received a dummy injection.

The researchers said it worked out at 70% protection, which is better than the seasonal flu jab.

Nobody getting the actual vaccine developed severe-Covid or needed hospital treatment.

Prof Andrew Pollard, the trial's lead investigator, said he was "really pleased" with the results as "it means we have a vaccine for the world".

However, protection was 90% in an analysis of around 3,000 people on the trial who were given a half-sized first dose and a full-sized second dose.

Prof Pollard said the finding was "intriguing" and would mean "we would have a lot more doses to distribute."

The analysis also suggested there was a reduction in the number of people being infected without developing symptoms, who are still thought to be able to spread the virus.